Skip to main content

Alimera Sciences Inc

ALIMDelisted Sep 16, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001267602

Alimera Sciences Inc was delisted on Sep 16, 2024; its insiders filed their last Form 4 on Sep 18, 2024; 52 institutions reported holding it in 13F filings for Q2 2024, worth $257.9M in total; no superinvestor held it.

Holders of 5% or more of ALIM

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Alimera Sciences Inc, largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Alimera Sciences Inc on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

38 Schedule 13D and 13G filings on Alimera Sciences Inc, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on ALIM
Filed (ET)FilerFormStakeChangeEvent dateFiling
Nov 13, 2024Stonepine Capital Management, LLC13G/AOld format–––SEC
Nov 7, 2024Boothbay Fund Management, LLC13G/AOld format–––SEC
Sep 18, 2024Caligan Partners LP13D/AOld format–––SEC
Sep 16, 2024Velan Capital Investment Management LP13D/AOld format–––SEC
Jun 24, 2024Caligan Partners LP13D/AOld format–––SEC
May 16, 2024Velan Capital Investment Management LP13D/AOld format–––SEC
Feb 14, 2024Lytton Laurence W13G/AOld format–––SEC
Feb 13, 2024Altium Capital Management LP13G/AOld format–––SEC
Feb 13, 2024Boothbay Fund Management, LLC13G/AOld format–––SEC
Feb 13, 2024HBM Healthcare Investments (Cayman) Ltd.13G/AOld format–––SEC
Feb 13, 2024Stonepine Capital Management, LLC13G/AOld format–––SEC
Dec 8, 2023Morgan Stanley13G/AOld format–––SEC
Aug 23, 2023Altium Capital Management LP13GOld format–New–SEC
Aug 16, 2023Velan Capital Investment Management LP13D/AOld format–––SEC
Aug 14, 2023Lytton Laurence W13GOld format–New–SEC
Aug 10, 2023Boothbay Fund Management, LLC13GOld format–New–SEC
Aug 10, 2023Stonepine Capital Management, LLC13GOld format–New–SEC
Aug 3, 2023Velan Capital Investment Management LP13D/AOld format–––SEC
Aug 3, 2023Caligan Partners LP13D/AOld format–––SEC
May 19, 2023Velan Capital Investment Management LP13D/AOld format–––SEC
May 18, 2023Caligan Partners LP13D/AOld format–––SEC
Apr 3, 2023Palo Alto Investors LP13G/AOld format–––SEC
Mar 31, 2023Velan Capital Investment Management LP13DOld format–New–SEC
Mar 28, 2023Caligan Partners LP13D/AOld format–––SEC
Feb 14, 2023Palo Alto Investors LP13G/AOld format–––SEC
Feb 8, 2023Morgan Stanley13G/AOld format–––SEC
Oct 27, 2022Morgan Stanley13G/AOld format–––SEC
May 25, 2022Caligan Partners LP13DOld format–New–SEC
Mar 10, 2022Morgan Stanley13G/AOld format–––SEC
Feb 14, 2022Palo Alto Investors LP13G/AOld format–––SEC
Feb 10, 2022Morgan Stanley13G/AOld format–––SEC
Feb 3, 2022Hirschman Orin13G/AOld format–––SEC
Apr 30, 2021Ocumension Therapeutics13GOld format–New–SEC
Feb 16, 2021Palo Alto Investors LP13G/AOld format–––SEC
Feb 12, 2021Flynn James E13G/AOld format–––SEC
Feb 12, 2021Avoro Capital Advisors LLC13G/AOld format–––SEC
Feb 10, 2021Hirschman Orin13G/AOld format–––SEC
Feb 10, 2021Morgan Stanley13G/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Alimera Sciences Inc shares.

No Form 144 notices for Alimera Sciences Inc are on file.